Saltar al contenido
Merck
Todas las fotos(2)

Documentos clave

Ver Toda la documentación

N158

Sigma-Aldrich

Naftopidil hydrochloride hydrate

solid

Sinónimos:

4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrochloride hydrate, KT-611

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
C24H28N2O3 · xHCl · yH2O
Número de CAS:
57149-07-2
Peso molecular:
392.49 (anhydrous free base basis)
MDL number:
MFCD11046013
UNSPSC Code:
12352200
PubChem Substance ID:
24277790
NACRES:
NA.77

form

solid

Quality Level

200

color

white

solubility

methanol: >10 mg/mL
H2O: insoluble

SMILES string

O.Cl.COc1ccccc1N2CCN(CC2)CC(O)COc3cccc4ccccc34

InChI

1S/C24H28N2O3.ClH.H2O/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23;;/h2-12,20,27H,13-18H2,1H3;1H;1H2

InChI key

INIDYCYXDNFBSV-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Biochem/physiol Actions

α1-Adrenoceptor antagonist; antihypertensive.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
SLCL0010
SLBQ0653V
SLBK9994V
SLBH4087V
099K1235

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Teruhiko Yokoyama et al.
International journal of urology : official journal of the Japanese Urological Association, 18(3), 225-230 (2011-01-29)
The aim of the present study was to explore the effects of three different types of alpha-1 adrenoceptor blockers (α1-blocker) on lower urinary tract symptoms (LUTS), erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in patients with benign prostatic hyperplasia. A
Eriko Masachika et al.
Anticancer research, 33(3), 887-894 (2013-03-14)
Naftopidil, an α1-adrenoceptor blocker, has been clinically used for the treatment of benign prostate hyperplasia and hypertension. Emerging evidence has shown that naftopidil exhibits an antitumor effect on a variety of cancer types including prostate cancer. The aim of the
Hideki Sakai et al.
Hinyokika kiyo. Acta urologica Japonica, 57(1), 7-13 (2011-02-10)
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50
Yasuo Tsuzaka et al.
International journal of urology : official journal of the Japanese Urological Association, 18(11), 792-795 (2011-09-16)
The aim of the present study was to compare the efficacy of the selective α(1D) -adrenoceptor antagonist naftopidil and the selective α(1A) -adrenoceptor antagonist silodosin (as an example) in the management of ureteral stones in Japanese male patients. A total
Hideyasu Tsumura et al.
International journal of radiation oncology, biology, physics, 81(4), e385-e392 (2011-06-15)
To compare the efficacy of three α(1A)/α(1D)-adrenoceptor (AR) antagonists--naftopidil, tamsulosin, and silodosin--that have differing affinities for the α(1)-AR subtypes in treating urinary morbidities in Japanese men with (125)I prostate implantation (PI) for prostate cancer. This single-institution prospective randomized controlled trial
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico